Skip to main content
Equibles
KARD logo

KARD · Kardigan, Inc. · Metrics

Track KARD — free

Use KARD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KARD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$15.52 +1.66 (+11.98%) At close · Nov 6
Russell 2000 member Rebalance outlook locked
Going-concern doubt — cleared Aug 11, 2026

The latest filing states the doubt was alleviated.

“The Company previously concluded that recurring losses, negative cash flows from operations, and limited liquidity raised substantial doubt about its ability to continue as a going concern. In June 2026, the Company completed its IPO and received net proceeds of approximately $422.4 million. Upon closing of the IPO and receipt of the associated net proceeds, the Company alleviated the substantial doubt that previously existed.”
View the 10-Q filed Aug 11, 2026
Market Cap
$1.30B
Shares
93.50M
Volume · Nov 6 406.63K Avg daily vol (3M) 574.06K

KARD metrics

34 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$15.52
Market cap
$1.30B

Price action

23 metrics
Price change (1W)
-3.1%
Price change (30D)
+0.2%
Price change (3M)
-31.9%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
72.6%
Annualized volatility (3M)
74.2%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
46.4
Price vs SMA 50
-12.4%
Price vs SMA 200
—
Avg volume (3M)
571,642
Relative volume
1.2
Average dollar volume
$9.21M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
93.50M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.1
reciprocal yield 47.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-15.31

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+103.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
—
Debt / equity
0.0
Current ratio
8.7
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
8.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$384.00M
Latest balance sheet
Cash & equivalents
$384.00M
Total assets
$721.79M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
69
13F filer change QoQ
+69
Institutional ownership
61.2%
Conviction holders (share of 13F filers)
4.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
1.0
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.1%

Short interest

3 metrics
Short interest
5.7%
Latest settlement · 7.6 days to cover
Days to cover
7.6d
Short-squeeze score
68 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 2123613 CUSIP 485925101 13F (30d) 14 filings 14 filers Visit website Investor relations